Human Genome Sciences and Aegera Therapeutics Announce Initiation of Clinical Trial of Lead IAP...
ROCKVILLE, Md. & MONTREAL----Human Genome Sciences, Inc. and Aegera Therapeutics, Inc. today announced that HGS has initiated dosing in a Phase 1 clinical trial to evaluate the safety and tolerability of its lead IAP inhibitor,...



